Medicinova (MNOV) Non-Current Deferred Tax Liability (2010 - 2026)
Medicinova (MNOV) posted quarterly Non-Current Deferred Tax Liability of $201792.0 for Q4 2025, little changed year-over-year from $201792.0 in Q4 2024, and little changed quarter-over-quarter from $201792.0 in Q3 2025.
Medicinova (MNOV) Non-Current Deferred Tax Liability (2010 - 2026) Analysis & Trends
Medicinova (MNOV) has reported Non-Current Deferred Tax Liability for 16 consecutive years, with $201792.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $201792.0; the TTM figure through Dec 2025 stood at $201792.0 (changed 0.0% YoY), while the FY2025 annual figure was $201792.0, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability held at $201792.0 in Q4 2025 per MNOV's latest filing, from $201792.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $201792.0 in Q1 2021 and bottomed at $201792.0 in Q1 2021.
- Historically, Non-Current Deferred Tax Liability has averaged $201792.0 across 5 years, with a median of $201792.0 in 2021.
- On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 0.0% in 2021 and fell as far as 0.0% in 2021.
- Medicinova's Non-Current Deferred Tax Liability stood at $201792.0 in 2021, then changed by 0.0% to $201792.0 in 2022, then changed by 0.0% to $201792.0 in 2023, then changed by 0.0% to $201792.0 in 2024, then changed by 0.0% to $201792.0 in 2025.
- Business Quant data shows MNOV's Non-Current Deferred Tax Liability at $201792.0 in Q4 2025, $201792.0 in Q3 2025, and $201792.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Medicinova | 68.42 Mn | 68.42 Mn | 317,759.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 201,792.00 |
| Jun 30, 2026 | 201,792.00 |
| Dec 31, 2025 | 201,792.00 |
| Dec 31, 2025 | 201,792.00 |
| Sep 30, 2025 | 201,792.00 |
| Sep 30, 2025 | 201,792.00 |
| Jun 30, 2025 | 201,792.00 |
| Jun 30, 2025 | 201,792.00 |
| Mar 31, 2025 | 201,792.00 |
| Mar 31, 2025 | 201,792.00 |
| Dec 31, 2024 | 201,792.00 |
| Dec 31, 2024 | 201,792.00 |
| Sep 30, 2024 | 201,792.00 |
| Sep 30, 2024 | 201,792.00 |
| Jun 30, 2024 | 201,792.00 |
| Jun 30, 2024 | 201,792.00 |
| Mar 31, 2024 | 201,792.00 |
| Mar 31, 2024 | 201,792.00 |
| Dec 31, 2023 | 201,792.00 |
| Dec 31, 2023 | 201,792.00 |